BRIDGING SCIENCE AND CAPITAL
Specialist equity research for
ASX life sciences and healthcare
Bridge Life Sciences analyses ASX-listed therapeutics, diagnostics, medical technology and digital health companies, connecting scientific and clinical evidence with commercial prospects, funding requirements and valuation.
View the latest research reports
Independent of capital raisings
Every report free to read
Clear reasoning and disclosures
WhY CHOOSE BRIDGE LIFE SCIENCES
Understand the science. Assess the investment case.
Life sciences investing requires more than a headline result. Clinical evidence, regulatory pathways, market opportunity and access to capital all shape the investment case.
Bridge Life Sciences brings these elements together in clear, evidence-based equity research, helping investors assess the opportunities, risks and milestones that matter.

Our APPROACH
Connecting the science and the financial case
01
Scientific and clinical analysis
We examine a company's study designs, clinical results and regulatory pathways to assess what the evidence supports – and where uncertainty remains.
02
Commercial and financial assessment
We assess the company's market opportunity, competition and funding requirements, and assess the drivers of the investment case to develop our valuation.
03
Clear reasoning and disclosures
We explain the assumptions behind our analysis as well as the principal risks, and disclose how the research is funded.
Coverage
Equity research across life sciences and healthcare
Therapeutics
Diagnostics
Medical technology
Digital health
In-depth coverage that develops over time – not just a single report.
Start with the research.
Explore our latest company research and commentary on ASX life sciences and healthcare.
General information only. See Legal and Disclaimer.